Caribou Biosciences (CRBU) Competitors $2.21 +0.25 (+12.76%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRBU vs. PSTX, SOPH, VXRT, FATE, CLLS, RLAY, ANNX, ERAS, ABUS, and OCSShould you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Poseida Therapeutics (PSTX), SOPHiA GENETICS (SOPH), Vaxart (VXRT), Fate Therapeutics (FATE), Cellectis (CLLS), Relay Therapeutics (RLAY), Annexon (ANNX), Erasca (ERAS), Arbutus Biopharma (ABUS), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Caribou Biosciences vs. Poseida Therapeutics SOPHiA GENETICS Vaxart Fate Therapeutics Cellectis Relay Therapeutics Annexon Erasca Arbutus Biopharma Oculis Caribou Biosciences (NASDAQ:CRBU) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Do insiders & institutionals have more ownership in CRBU or PSTX? 77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Comparatively, 2.9% of Poseida Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, CRBU or PSTX? Caribou Biosciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Do analysts recommend CRBU or PSTX? Caribou Biosciences currently has a consensus target price of $11.25, indicating a potential upside of 409.05%. Poseida Therapeutics has a consensus target price of $15.00, indicating a potential upside of 507.29%. Given Poseida Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Poseida Therapeutics is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Poseida Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CRBU or PSTX? Poseida Therapeutics received 16 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 67.86% of users gave Poseida Therapeutics an outperform vote while only 57.89% of users gave Caribou Biosciences an outperform vote. CompanyUnderperformOutperformCaribou BiosciencesOutperform Votes2257.89% Underperform Votes1642.11% Poseida TherapeuticsOutperform Votes3867.86% Underperform Votes1832.14% Does the media prefer CRBU or PSTX? In the previous week, Poseida Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Poseida Therapeutics and 0 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.42 beat Poseida Therapeutics' score of 0.20 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Overall Sentiment Caribou Biosciences Neutral Poseida Therapeutics Neutral Is CRBU or PSTX more profitable? Poseida Therapeutics has a net margin of -127.48% compared to Caribou Biosciences' net margin of -372.78%. Caribou Biosciences' return on equity of -34.76% beat Poseida Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-372.78% -34.76% -29.58% Poseida Therapeutics -127.48%-121.01%-39.66% Which has preferable valuation & earnings, CRBU or PSTX? Caribou Biosciences has higher earnings, but lower revenue than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$34.48M5.79-$102.07M-$1.39-1.59Poseida Therapeutics$88.46M2.71-$123.43M-$1.19-2.08 SummaryCaribou Biosciences beats Poseida Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition Export to ExcelMetricCaribou BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$199.70M$3.14B$5.50B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E Ratio-1.5912.03116.1015.23Price / Sales5.79400.761,496.2597.74Price / CashN/A149.0039.7434.10Price / Book0.534.024.775.07Net Income-$102.07M-$42.25M$119.06M$225.46M7 Day Performance24.86%8.04%0.80%0.37%1 Month Performance24.16%8.69%5.65%3.57%1 Year Performance-40.27%32.09%36.75%29.43% Caribou Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.1437 of 5 stars$2.21+12.8%$11.25+409.0%-38.3%$199.70M$34.48M-1.59100Upcoming EarningsPSTXPoseida Therapeutics3.662 of 5 stars$2.47+4.2%$15.00+507.3%+19.3%$230.21M$88.46M-2.08260Analyst ForecastSOPHSOPHiA GENETICS1.7976 of 5 stars$3.64+1.7%$6.50+78.6%-4.7%$234.04M$62.37M-3.57520Upcoming EarningsGap UpVXRTVaxart1.9345 of 5 stars$0.77flat$3.00+289.7%+19.2%$135.78M$15.65M-1.67109Upcoming EarningsNews CoverageFATEFate Therapeutics3.633 of 5 stars$2.43+2.5%$6.90+184.0%+25.9%$276.73M$63.53M-1.42550Short Interest ↑Gap UpCLLSCellectis2.5221 of 5 stars$1.80+1.1%$8.00+344.4%-31.8%$100.05M$13.03M-1.30290Upcoming EarningsNews CoverageRLAYRelay Therapeutics3.2161 of 5 stars$5.84+3.7%$21.11+261.5%-14.5%$781.92M$25.55M-2.32304Upcoming EarningsNews CoverageANNXAnnexon1.457 of 5 stars$7.28-0.5%$15.80+117.0%+203.3%$769.13MN/A-5.9260ERASErasca2.6255 of 5 stars$2.72+5.0%$6.10+124.3%+19.8%$768.40MN/A-2.96126ABUSArbutus Biopharma2.3082 of 5 stars$3.96+2.9%$5.25+32.6%+115.2%$725.87M$18.14M-8.8073Upcoming EarningsOCSOculis2.1656 of 5 stars$17.88+4.1%$29.20+63.3%+96.5%$724.14M$980,000.00-9.312High Trading Volume Related Companies and Tools Related Companies Poseida Therapeutics Competitors SOPHiA GENETICS Competitors Vaxart Competitors Fate Therapeutics Competitors Cellectis Competitors Relay Therapeutics Competitors Annexon Competitors Erasca Competitors Arbutus Biopharma Competitors Oculis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRBU) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
